IPO Year: 2022
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/16/2024 | $16.00 | Neutral → Buy | Ladenburg Thalmann |
| 4/29/2024 | Buy → Neutral | Ladenburg Thalmann | |
| 3/1/2024 | $14.00 | Mkt Outperform | JMP Securities |
| 12/15/2023 | $17.00 → $12.00 | Buy | Jefferies |
| 10/5/2023 | Buy | Maxim Group | |
| 6/2/2023 | $25.00 | Outperform | Oppenheimer |
| 5/8/2023 | $25.00 | Outperform | BMO Capital Markets |
| 4/27/2023 | $22.00 | Buy | Ladenburg Thalmann |
| 4/20/2023 | $24.00 | Buy | H.C. Wainwright |
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
SC 13D/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
– Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient selection (p = 0.009) from ongoing ACR-368 registrational-intent Phase 2b endometrial cancer study presented at ESMO – Endometrial cancer, a tumor type identified by AP3 as particularly sensitive to ACR-368 treatment, represents the first potential approval opportunity for ACR-368, in second line, with options to move into the front-line setting being evaluated – Completed planned enrollment of first dose-escalation cohort in ongoing Phase 1 study of ACR-2316, company's second clinical stage asset, internally discovered using AP3 – Cash, cas
AP3-identified clinical biomarkers for ACR-368 led to the development of a response-predictive OncoSignature assay which has shown statistically significant prospective validation and responder enrichment in the ongoing registrational-intent Phase 2b studyACR-2316, a novel WEE1/PKMYT1 inhibitor, was uniquely enabled and optimized by AP3 to deliver superior single agent activity, complete tumor regression and pro-apoptotic tumor cell death through potent activation of CDK1, CDK2, and PLK1Acrivon scientists to present data at two key scientific conferences demonstrating AP3's proprietary and actionable machine learning-driven capabilities for drug discovery and clinical development WATERTOWN,
WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today announced that the company approved a grant of equity awards under its 2023 Inducement Plan to certain employees. The equity awards were granted in the form of stock options and have a grant date of October 15, 2024. The employees received an aggregate of options to purchase 61,9
- First patient dosed two quarters ahead of original timelines in Acrivon Phase 1 study to assess safety and tolerability of ACR-2316 - ACR-2316 was internally discovered and advanced in 15 months from initial lead to Phase 1 trial initiation uniquely enabled by AP3 - ACR-2316 was rationally designed by AP3 to deliver complete tumor regression and pro-apoptotic tumor cell death through potent activation of CDK1, CDK2, and PLK1 - Initial clinical data from the monotherapy Phase 1 dose optimization trial expected in 2H 2025 WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medici
Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically significant segregation of responders in BM+ vs BM- subgroups based on OncoSignature patient selection (p-value = 0.009) ACR-368 endometrial cohort data maturing with all responders still on therapy; mDoR not yet reached (~6 months at time of data-cut) Endometrial cancer now anticipated to be the first tumor type with potential for ACR-368 accelerated regulatory approval IND clearance and initial sites activated ahead of timelines for ACR-2316 with first-in-human dosing anticipated in Q4 2024 AP3
WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, September 17, 2024 at 8:35 a.m. ET at the Cantor Global Healthcare Conference in New York. To access the live webcast, visit the Events
-Webcast investor event on September 14, 2024 at 9:00 a.m. ET -ESMO poster presentation to provide updated ACR-368 clinical data in endometrial cancer -Webcast to provide updates on its lead assets ACR-368, ACR-2316, and its AP3 platform WATERTOWN, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today announced that the company will host a
WATERTOWN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acrivon Precision Predictive Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today reported financial results for the second quarter ended June 30, 2024 and reviewed business highlights. "We continue to make significant progress on our mission to deliver on the unique and actionable capabilities of our AP3 platform by rapidly advancing a pipeline of different
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Wednesday, June 5, 2024 at 9:30 a.m. ET at the Jefferies Global Healthcare Conference in New York. To access
WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today reported financial results for the first quarter ended March 31, 2024 and reviewed business highlights. "Within the first few months of 2024, we have demonstrated significant progress across our AP3 platform and our clinical and preclinical pip
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
Ladenburg Thalmann upgraded Acrivon Therapeutics from Neutral to Buy and set a new price target of $16.00
Ladenburg Thalmann downgraded Acrivon Therapeutics from Buy to Neutral
JMP Securities initiated coverage of Acrivon Therapeutics with a rating of Mkt Outperform and set a new price target of $14.00
Jefferies resumed coverage of Acrivon Therapeutics with a rating of Buy and set a new price target of $12.00 from $17.00 previously
Maxim Group initiated coverage of Acrivon Therapeutics with a rating of Buy
Oppenheimer initiated coverage of Acrivon Therapeutics with a rating of Outperform and set a new price target of $25.00
BMO Capital Markets initiated coverage of Acrivon Therapeutics with a rating of Outperform and set a new price target of $25.00
Ladenburg Thalmann initiated coverage of Acrivon Therapeutics with a rating of Buy and set a new price target of $22.00
H.C. Wainwright initiated coverage of Acrivon Therapeutics with a rating of Buy and set a new price target of $24.00
BMO Capital analyst Etzer Darout reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and maintains $25 price target.
HC Wainwright & Co. analyst Emily Bodnar maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and raises the price target from $20 to $22.
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.84) by 13.1 percent. This is a 25.86 percent decrease over losses of $(0.58) per share from the same period last year.
Ladenburg Thalmann analyst Aydin Huseynov downgrades Acrivon Therapeutics (NASDAQ:ACRV) from Buy to Neutral.
BMO Capital analyst Etzer Darout maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and raises the price target from $18 to $25.
JMP Securities analyst Silvan Tuerkcan maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and raises the price target from $14 to $17.
Piper Sandler analyst Joseph Catanzaro maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight and raises the price target from $26 to $30.
HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $20 price target.
WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided business highlights. "On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year
WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors. "Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation precisi
WATERTOWN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D., to its board of directors. "We are excited to welcome Ivana to our board of directors," said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and fou
WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Jean-Marie Cuillerot, M.D., as chief medical officer. "Jean-Marie has over twenty years of successful experience in oncology drug development, and we are delighted to have him join Acrivon," said Peter Blume-Jense
WATERTOWN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced that Adam D. Levy, Ph.D., M.B.A., has joined Acrivon as senior vice president and head, investor relations and corporate affairs. "We are thrilled to have Adam join us as a proven leader in investor relations and corporate strategy," said Peter Blume-Jensen, M.D., Ph.D., chief ex
WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced that Charles (Chuck) Baum, M.D., Ph.D., founder, president, head of research and development, board member, and former chief executive officer of Mirati Therapeutics, has been appointed to Acrivon's board of directors. "We are thrilled about Chuck's appointment and look forward
10-Q - Acrivon Therapeutics, Inc. (0001781174) (Filer)
8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
10-Q - Acrivon Therapeutics, Inc. (0001781174) (Filer)
8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
10-Q - Acrivon Therapeutics, Inc. (0001781174) (Filer)
EFFECT - Acrivon Therapeutics, Inc. (0001781174) (Filer)
ARS - Acrivon Therapeutics, Inc. (0001781174) (Filer)